1-866-598-7166

Ablative Radioembolization of Renal Cell Carcinoma Trial (ARRCC)

Trial ID: NCT06642220
Kidney Cancer Type: Any subtype


Background:

Selective Internal Radiation Therapy (SIRT), also known as radioembolization, involves sending tiny radioactive beads (containing a material called yttrium-90) directly into the blood vessels that feed the tumour. Once they reach the tumor, the beads give off radiation, damaging the cancer cells and making it difficult for them to survive. This method is already used to treat large tumours in the liver, and researchers want to see if it can also help treat large kidney tumours in people who aren’t able to have surgery.


The Trial:

This study will investigate the effectiveness of radioembolization – specifically, how this therapy helps to slow down the growth or spread of kidney cancer and how well it can preserve kidney function. 

All participants will be assigned to the same treatment regime. 


Basic Eligibility:

  • Diagnosed with kidney cancer (renal cell carcinoma)
  • Tumor is larger than 4cm but has not spread into large blood vessels near the kidney
  • Not a candidate for surgery to remove the tumor

 

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreLondon Health Sciences Centre - Victoria Hospital Principal InvestigatorCraig Johnson LocationLondon, ON Trial StatusRecruiting
Kidney Cancer Canada